Q32 BIO INC (QTTB) Stock Price & Overview
NASDAQ:QTTB • US7469641051
The current stock price of QTTB is 4.89 USD. Today QTTB is down by -1.21%. In the past month the price increased by 22.86%. In the past year, price increased by 120.27%.
QTTB Key Statistics
- Market Cap
- 60.147M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
QTTB Stock Performance
QTTB Stock Chart
QTTB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to QTTB. When comparing the yearly performance of all stocks, QTTB is one of the better performing stocks in the market, outperforming 95.55% of all stocks.
QTTB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QTTB. QTTB has a bad profitability rating. Also its financial health evaluation is rather negative.
QTTB Earnings
QTTB Forecast & Estimates
8 analysts have analysed QTTB and the average price target is 15.3 USD. This implies a price increase of 212.88% is expected in the next year compared to the current price of 4.89.
QTTB Groups
Sector & Classification
QTTB Financial Highlights
Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 84.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QTTB Ownership
QTTB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 413.319B | ||
| AMGN | AMGEN INC | 16.73 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.1 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 308.97 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About QTTB
Company Profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2018-03-28. The firm is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The firm is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
Company Info
Q32 BIO INC
830 Winter Street
Waltham MASSACHUSETTS US
Employees: 26
Phone: 17819990232
Q32 BIO INC / QTTB FAQ
Can you describe the business of Q32 BIO INC?
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2018-03-28. The firm is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The firm is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
What is the current price of QTTB stock?
The current stock price of QTTB is 4.89 USD. The price decreased by -1.21% in the last trading session.
Does Q32 BIO INC pay dividends?
QTTB does not pay a dividend.
What is the ChartMill rating of Q32 BIO INC stock?
QTTB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is Q32 BIO INC (QTTB) stock traded?
QTTB stock is listed on the Nasdaq exchange.
What is the market capitalization of QTTB stock?
Q32 BIO INC (QTTB) has a market capitalization of 60.15M USD. This makes QTTB a Micro Cap stock.